Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 689859, 15 pages
http://dx.doi.org/10.1155/2008/689859
Review Article

Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template

Institute of Molecular and Cellular Biosciences, University of Tokyo, Yayoi Bunkyo-ku, Tokyo 113-0032, Japan

Received 17 August 2007; Revised 9 November 2007; Accepted 26 December 2007

Academic Editor: F. Gregoire

Copyright © 2008 Hiroyuki Miyachi and Yuichi Hashimoto. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Chawta, J. J. Repa, R. M. Evans, and D. J. Mangelsdorf, “Nuclear receptors and lipid physiology: opening the x-files,” Science, vol. 294, no. 5548, pp. 1866–1870, 2001. View at Publisher · View at Google Scholar · View at PubMed
  2. N. J. McKenna, R. B. Lanz, and B. W. O'Malley, “Nuclear receptor coregulators: cellular and molecular biology,” Endocrine Reviews, vol. 20, no. 3, pp. 321–344, 1999. View at Publisher · View at Google Scholar
  3. V. Giguere, “Orphan nuclear receptors: from gene to function,” Endocrine Reviews, vol. 20, no. 5, pp. 689–725, 1999. View at Publisher · View at Google Scholar
  4. C. D. Banner, M. Gottlicher, E. Widmark, J. Sjovall, J. J. Rafter, and J. A. Gustafsson, “A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma,” Journal of Lipid Research, vol. 34, no. 9, pp. 1583–1591, 1993. View at Google Scholar
  5. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  6. H. Keller, C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli, “Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2160–2164, 1993. View at Publisher · View at Google Scholar
  7. B. Staels and J. Auwerx, “Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones,” Current Pharmaceutical Design, vol. 3, no. 1, pp. 1–14, 1997. View at Google Scholar
  8. A. Okuno, H. Tamemoto, K. Tobe et al., “Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1354–1361, 1998. View at Publisher · View at Google Scholar · View at PubMed
  9. H. Lim, R. A. Gupta, W.-G. Ma et al., “Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ,” Genes & Development, vol. 13, no. 12, pp. 1561–1574, 1999. View at Google Scholar
  10. M. L. Sznaidman, C. D. Haffner, P. R. Maloney et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003. View at Publisher · View at Google Scholar
  11. W. R. Oliver, Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
  12. T. Tanaka, J. Yamamoto, S. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. O. Dewald, S. Sharma, J. Adrogue et al., “Downregulation of peroxisome proliferator-activated receptor-α gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity,” Circulation, vol. 112, no. 3, pp. 407–415, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. M. Mendez and M. C. LaPointe, “PPARγ inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes,” Hypertension, vol. 42, no. 4, pp. 844–850, 2003. View at Publisher · View at Google Scholar · View at PubMed
  15. R. F. Morrison and S. R. Farmer, “Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17088–17097, 1999. View at Publisher · View at Google Scholar
  16. J.-W. Huang, C.-W. Shiau, J. Yang et al., “Development of small-molecule cyclin D1-ablative agents,” Journal of Medicinal Chemistry, vol. 49, no. 15, pp. 4684–4689, 2006. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Sato, “Peroxisome proliferator activated receptor ligands and angiogenesis,” Nippon Rinsho, vol. 63, no. 4, pp. 603–608, 2005. View at Google Scholar
  18. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Genetic- or transforming growth factor-β1-induced changes in epidermal peroxisome proliferator-activated receptor β/δ expression dictate wound repair kinetics,” Journal of Biological Chemistry, vol. 280, no. 18, pp. 18163–18170, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. N. S. Tan, L. Michalik, N. Di-Poï et al., “Essential role of Smad3 in the inhibition of inflammation-induced PPARβ/δ expression,” The EMBO Journal, vol. 23, no. 21, pp. 4211–4221, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. A. D. Burdick, M. T. Bility, E. E. Girroir et al., “Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes,” Cellular Signalling, vol. 19, no. 6, pp. 1163–1171, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. Y. Hashimoto and H. Miyachi, “Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis,” Bioorganic and Medicinal Chemistry, vol. 13, no. 17, pp. 5080–5093, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003. View at Publisher · View at Google Scholar
  23. K. Murakami, K. Tobe, T. Ide et al., “A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats,” Diabetes, vol. 47, no. 12, pp. 1841–1847, 1998. View at Publisher · View at Google Scholar
  24. M. Nomura, S. Kinoshita, H. Satoh et al., “(3-substituted benzyl)thiazolidine-2, 4-diones as structurally new antihyperglycemic agents,” Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 4, pp. 533–538, 1999. View at Publisher · View at Google Scholar
  25. K. Yajima, H. Hirose, H. Fujita et al., “Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice,” American Journal of Physiology, vol. 284, no. 5, pp. E966–E971, 2003. View at Google Scholar
  26. M. Nomura, T. Tanase, and H. Miyachi, “Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor α,” Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 16, pp. 2101–2104, 2002. View at Publisher · View at Google Scholar
  27. H. Miyachi, M. Nomura, T. Tanase, M. Suzuki, K. Murakami, and K. Awano, “Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor α,” Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 3, pp. 333–335, 2002. View at Publisher · View at Google Scholar
  28. H. Miyachi, M. Nomura, T. Tanase et al., “Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARα-selective activators,” Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 1, pp. 77–80, 2002. View at Publisher · View at Google Scholar
  29. M. Nomura, T. Tanase, T. Ide et al., “Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators,” Journal of Medicinal Chemistry, vol. 46, no. 17, pp. 3581–3599, 2003. View at Publisher · View at Google Scholar · View at PubMed
  30. H. Keller, P. R. Devchand, M. Perroud, and W. Wahli, “PPARα structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents,” Biological Chemistry, vol. 378, no. 7, pp. 651–655, 1997. View at Google Scholar
  31. P. J. Brown, D. A. Winegar, K. D. Plunket et al., “A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity,” Journal of Medicinal Chemistry, vol. 42, no. 19, pp. 3785–3788, 1999. View at Publisher · View at Google Scholar
  32. M. Nagasawa, T. Ide, M. Suzuki et al., “Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor α (PPARα) agonist in dogs,” Biochemical Pharmacology, vol. 67, no. 11, pp. 2057–2069, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. H. Miyachi and H. Uchiki, “Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor α (PPARα)-activation by phenylpropanoic acid-type PPARα agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 19, pp. 3145–3149, 2003. View at Publisher · View at Google Scholar
  34. H. Uchiki and H. Miyachi, “Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) α agonist; possible mechanism(s) of human PPARα selectivity of an α-substituted phenylpropanoic acid derivative (KCL),” Chemical and Pharmaceutical Bulletin, vol. 52, no. 3, pp. 365–367, 2004. View at Publisher · View at Google Scholar
  35. P. J. Brown, T. A. Smith-Oliver, P. S. Charifson et al., “Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library,” Chemistry & Biology, vol. 4, no. 12, pp. 909–918, 1997. View at Publisher · View at Google Scholar
  36. Kalypsys, 2004, WO2004092117-A.
  37. N. Mahindroo, C.-F. Huang, Y.-H. Peng et al., “Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities,” Journal of Medicinal Chemistry, vol. 48, no. 26, pp. 8194–8208, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. W. R. Oliver, Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at PubMed
  39. M. L. Sznaidman, C. D. Haffner, and P. R. Maloney, “Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003. View at Publisher · View at Google Scholar
  40. C. E. Basséne, F. Suzenet, N. Hennuyer et al., “Studies towards the conception of new selective PPARβ/δ ligands,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 17, pp. 4528–4532, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. S. Weigand, H. Bischoff, E. Dittrich-Wengenroth et al., “Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist,” Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 20, pp. 4619–4623, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. R. Epple, M. Azimioara, R. Russo et al., “1,3,5-trisubstituted aryls as highly selective PPARδ agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2969–2973, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. R. Epple, M. Azimioara, R. Russo et al., “3,4,5-trisubstituted isoxazoles as novel PPARδ agonists: part 2,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 21, pp. 5488–5492, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. R. Epple, R. Russo, M. Azimioara et al., “3,4,5-trisubstituted isoxazoles as novel PPARδ agonists: part 1,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 16, pp. 4376–4380, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome proliferator- activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999. View at Publisher · View at Google Scholar